Loading data for DRUG — first visit, this takes a few seconds.

アラート

Bright Minds Biosciences ... (DRUG)

NasdaqCM: DRUG · リアルタイム株価 · USD

84.74

+0.70 (0.83%)

終値時点： Aug 19, 2026, 8:00 PM

84.74

+0.00%

時間外: 7:30 PM

0.83% (1D)

データがありません

買気配	78.65
時価総額	831.47M
売上高（TTM）	n/a
純利益（TTM）	-24.51M
ベータ	0.09
EPS（TTM）	-2.05
PER（TTM）	n/a
予想PER	-13.19
PBR（TTM）	3.75
PSR（TTM）	n/a
Earnings Date	Dec 22, 2026

売気配	80.03
出来高	115,927
平均出来高（20日）	309,995
始値	85.80
前日終値	84.04
当日レンジ	83.24 - 87.00
52週レンジ	38.00 - 123.75
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

DRUGについて

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathi...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Mar 22, 2021

従業員数 26

上場取引所 NasdaqCM

ティッカー DRUG

ウェブサイト https://brightmindsbio.com

企業情報の全文

業績

2025年のBright Minds Biosciencesの売上高は0で、前年の0からundefined%の増加でした。利益は-12.23Mで、336.46%の増加でした。

財務諸表

決算サプライズ

Bright Minds BiosciencesはAug 14, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.24 で、予想を上回りました 1.40, うち 67.57% の前年比増加にあたります.

次回決算発表

Bright Minds Biosciences Inc.の決算発表予定日は Dec 22, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Zacks

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

3週間前 · Zacks

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren...

4週間前 · Zacks

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2か月前 · Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

4か月前 · Insider Monkey

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its fl...

2ページ中1ページ